Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target

被引：114

作者：

Krystof, Vladimir ^{[1
,2
]}

Baumli, Sonja ^{[3
]}

Fuerst, Robert ^{[4
]}

机构：

[1] Palacky Univ, Lab Growth Regulators, Fac Sci, Olomouc 78371, Czech Republic

[2] Inst Expt Bot ASCR, Olomouc 78371, Czech Republic

[3] Univ Newcastle, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England

[4] Univ Munich, Dept Pharm, Ctr Drug Res Pharmaceut Biol, D-81377 Munich, Germany

来源：

CURRENT PHARMACEUTICAL DESIGN | 2012年 / 18卷 / 20期

基金：

英国医学研究理事会;

关键词：

Cancer; inflammation; kinase; P-TEFb; inhibitor; therapeutics; angiogenesis; FLAVOPIRIDOL INDUCES APOPTOSIS; GROWTH-FACTOR EXPRESSION; MULTIPLE-MYELOMA CELLS; P-TEFB; TRANSCRIPTION ELONGATION; KAPPA-B; DOWN-REGULATION; CDK9/CYCLIN T1; SELICICLIB CYC202; CRYSTAL-STRUCTURE;

D O I：

10.2174/138161212800672750

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Deregulation of cyclin-dependent kinases (CDKs) has been associated with many cancer types and has evoked an interest in chemical inhibitors with possible therapeutic benefit. While most known inhibitors display broad selectivity towards multiple CDKs, recent work highlights CDK9 as the critical target responsible for the anticancer activity of clinically evaluated drugs. In this review, we discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 towards applications in cancer therapy. We also highlight the role of CDK9 in inflammatory processes and diseases.

引用

页码：2883 / 2890

页数：8

共 86 条

[1] SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor [J].

Ali, M. Aktar ;

Choy, Hak ;

Habib, Amyn A. ;

Saha, Debabrata .

NEOPLASIA, 2007, 9 (05) :370-381

[2]

Arguello F, 1998, BLOOD, V91, P2482

[3] The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing rad51 expression in a p53-dependent manner [J].

Arnbrosini, Grazia ;

Seehnan, Sharon L. ;

Qin, Li-Xuan ;

Schwartz, Gary K. .

CANCER RESEARCH, 2008, 68 (07) :2312-2320

[4] NF-κB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II [J].

Barboric, M ;

Nissen, RM ;

Kanazawa, S ;

Jabrane-Ferrat, N ;

Peterlin, BM .

MOLECULAR CELL, 2001, 8 (02) :327-337

[5] CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1 [J].

Bartkowiak, Bartlomiej ;

Liu, Pengda ;

Phatnani, Hemali P. ;

Fuda, Nicholas J. ;

Cooper, Jeffrey J. ;

Price, David H. ;

Adelman, Karen ;

Lis, John T. ;

Greenleaf, Arno L. .

GENES & DEVELOPMENT, 2010, 24 (20) :2303-2316

[6] The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation [J].

Baumli, Sonja ;

Lolli, Graziano ;

Lowe, Edward D. ;

Troiani, Sonia ;

Rusconi, Luisa ;

Bullock, Alex N. ;

Debreczeni, Judit E. ;

Knapp, Stefan ;

Johnson, Louise N. .

EMBO JOURNAL, 2008, 27 (13) :1907-1918

[7] Halogen Bonds Form the Basis for Selective P-TEFb Inhibition by DRB [J].

Baumli, Sonja ;

Endicott, Jane A. ;

Johnson, Louise N. .

CHEMISTRY & BIOLOGY, 2010, 17 (09) :931-936

[8] Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9 [J].

Berberich, Nina ;

Uhl, Bernd ;

Joore, Jos ;

Schmerwitz, Ulrike K. ;

Mayer, Bettina A. ;

Reichel, Christoph A. ;

Krombach, Fritz ;

Zahler, Stefan ;

Vollmar, Angelika M. ;

Fuerst, Robert .

BRITISH JOURNAL OF PHARMACOLOGY, 2011, 163 (05) :1086-1098

[9] CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases [J].

Bettayeb, K. ;

Oumata, N. ;

Echalier, A. ;

Ferandin, Y. ;

Endicott, J. A. ;

Galons, H. ;

Meijer, L. .

ONCOGENE, 2008, 27 (44) :5797-5807

[10]

Bettayeb Karima, 2010, Genes Cancer, V1, P369, DOI 10.1177/1947601910369817

← 1 2 3 4 5 6 7 8 9 →